Trial
NCT01482949
A Rollover Protocol for Subjects Previously Treated With AGS-003
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Argos Therapeutics
Collaborators
—
Condition
Renal Cell Carcinoma
Intervention
AGS-003
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-06-27